Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.73 |
| ▸ | MAOB | P27338 | 2/20 | 0.73 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828549 | 0.85 | MAOA (0.66) | MAOAMAOBMIFP2RX7 | |
| SCHEMBL29828653 | 0.84 | P2RX7 (0.67) | MAOAMAOBNOTUML3MBTL1POLB | |
| SCHEMBL18965289 | 0.83 | MAOA (0.63) | MAOAMAOBNOTUML3MBTL1POLB | |
| SCHEMBL25897470 | 0.82 | POLB (0.62) | MAOAMAOBNOTUML3MBTL1POLB | |
| SCHEMBL22532624 | 0.82 | MAOA (0.61) | MAOAMAOBNOTUML3MBTL1POLB | |
| SCHEMBL20046238 | 0.81 | MAOA (0.68) | MAOAMAOBNOTUML3MBTL1CA2 | |
| SCHEMBL22111817 | 0.80 | MIF (0.69) | NOTUML3MBTL1CA2CA9CA12 | |
| SCHEMBL3777938 | 0.80 | NOTUM (0.68) | MAOANOTUML3MBTL1POLBMIF | |
| SCHEMBL29980293 | 0.79 | MAOA (0.57) | MAOAMAOBL3MBTL1POLBCA2 | |
| SCHEMBL28935748 | 0.79 | MAOA (0.60) | MAOAMAOBNOTUML3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | RICTOR, MTOR, RPTOR | MAOA 3129/4885MAOB 3057/4885NOTUM 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.